Sign in

    Andres Maldonado

    Research Analyst at H.C. Wainwright & Co.

    Andres Y. Maldonado is an Equity Analyst at H.C. Wainwright & Co., specializing in biotechnology and life sciences, with particular focus on small- and mid-cap clinical-stage companies. He covers firms including ImmunityBio, Scholar Rock Holding, Ikena Oncology, Day One Biopharmaceuticals, Werewolf Therapeutics, and Aura Biosciences, consistently providing buy ratings and ambitious price targets. On TipRanks, he maintains a 3.52-star analyst status, with a noted success rate of around 13% and average returns fluctuating across recommendations, highlighted by exceptional gains such as a 271.5% return on Scholar Rock. Maldonado began his analyst career with H.C. Wainwright & Co., where he has advanced in coverage responsibility since at least 2022; his professional credentials include registered securities licenses and regulatory compliance with FINRA standards.

    Andres Maldonado's questions to Scholar Rock Holding (SRRK) leadership

    Andres Maldonado's questions to Scholar Rock Holding (SRRK) leadership • Q1 2025

    Question

    Andres Maldonado inquired about the potential for securing a commercial partner for Europe and how the company is prioritizing the development of apitegromab in additional indications.

    Answer

    CEO David Hallal firmly stated that securing a partner is not a priority, as the management team is highly experienced and fully capable of executing a global launch directly. He reiterated that decisions on expanding into new indications will be data-driven, with further updates to be provided by the R&D team later in the year.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to Day One Biopharmaceuticals (DAWN) leadership

    Andres Maldonado's questions to Day One Biopharmaceuticals (DAWN) leadership • Q1 2025

    Question

    Andres Maldonado from H.C. Wainwright & Co. asked about OJEMDA's long-term positioning against other therapies like MEK inhibitors and the company's appetite for business development given its strong cash position.

    Answer

    CEO Dr. Jeremy Bender explained the goal is to establish OJEMDA as the second-line standard of care for BRAF fusion pLGG by demonstrating a superior profile to entrenched off-label therapies. COO & CFO Charles York added that business development is critical for long-term growth and the company is actively evaluating opportunities with a high bar for investment, noting that adding one more program to the pipeline would be a great start.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to Day One Biopharmaceuticals (DAWN) leadership • Q4 2024

    Question

    Andres Maldonado asked about the assumptions underlying the FIREFLY-2 enrollment guidance, particularly regarding potential off-label frontline use of OJEMDA. He also questioned the conviction behind using an ADC modality for the unique PTK7 target.

    Answer

    CEO Jeremy Bender stated the FIREFLY-2 enrollment projection is based on real-time site enrollment rates and is not influenced by the very modest off-label frontline use observed. Regarding DAY301, he explained that conviction in the PTK7 target was established by a prior ADC program (cofetuzumab pelidotin) that showed efficacy, and Day One's thesis is that DAY301's different payload and properties will yield a superior therapeutic index.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to Day One Biopharmaceuticals (DAWN) leadership • Q3 2024

    Question

    Andres Maldonado of H.C. Wainwright & Co. asked about the ex-U.S. launch strategy with Ipsen and the development plan for the PTK7 ADC (DAY301), specifically regarding potential combination therapies.

    Answer

    CEO Jeremy Bender highlighted the strategic alignment with Ipsen for ex-U.S. registration, noting OJEMDA's unique Type 2 RAF inhibitor mechanism. Both Bender and Dr. Samuel Blackman, Head of R&D, stated the immediate focus for DAY301 is on demonstrating monotherapy activity before exploring combinations.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to I-Mab (IMAB) leadership

    Andres Maldonado's questions to I-Mab (IMAB) leadership • H1 2023

    Question

    Andres Maldonado asked how potential commercial partnerships, especially for uliledlimab, align with the new corporate vision.

    Answer

    CEO Raj Kannan explained that the company's current strategy is to leverage its strong balance sheet to advance its key assets independently. He believes it is premature to seek partners until more mature data is generated, which would maximize shareholder value. While I-Mab receives inbound interest, it is not actively pursuing a partnership at this time.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to I-Mab (IMAB) leadership • FY 2022

    Question

    Andres Maldonado from H.C. Wainwright requested more detail on the expected cash burn rate for 2023 and asked about the timing and financial considerations for bringing additional pipeline assets into the clinic.

    Answer

    Richard Yeh, Interim CFO and COO, projected the net cash burn rate for 2023 to be in the range of US$130 million to US$140 million, noting this would provide a cash runway of at least three years. Andrew Zhu, Acting CEO, added that while the company has a productive internal discovery engine, the current focus is on advancing the prioritized key assets to realize their value. He stated that the bar for in-licensing external assets is currently high but that this is a dynamic process that will be reassessed as the company generates cash flow from business development deals.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to I-Mab (IMAB) leadership • H1 2022

    Question

    Andres Maldonado asked for clarification on the commercialization strategy for felzartamab, questioning whether the hybrid model would be limited to multiple myeloma or also extend to autoimmune diseases, and what the expectations were for the deal size.

    Answer

    Jingwu Zang, Founder, Chairman and Acting CEO, confirmed that active discussions for a commercial partnership for felzartamab do include autoimmune disease indications, citing exciting recent data from MorphoSys. He stated the goal is to maximize the asset's value but declined to disclose the potential size of the partnership due to the confidential nature of ongoing negotiations.

    Ask Fintool Equity Research AI

    Andres Maldonado's questions to I-Mab (IMAB) leadership • Q4 2021

    Question

    Andres Maldonado asked how I-Mab's commercialization efforts will evolve in the coming year beyond manufacturing, and requested more details on the cash burn rate and any expected revenue milestone payments.

    Answer

    Jielun Zhu, Chief Strategy Officer, detailed the near-term portfolio strategy focused on hematologic oncology, aiming to cover 200-250 major hospitals and projecting $300-$400 million in revenue from 2023-2025. John Long, CFO, provided financial specifics, stating the 2021 operating cash burn was $165 million, with a projected burn of $180-$220 million for 2022-2023. He noted the current $671 million cash balance, plus over $250 million in expected milestone payments by 2025, is sufficient to fund operations for at least three years.

    Ask Fintool Equity Research AI